
PLATIND
NSEPrice History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Mixed MA signals — sideways/transition | Bearish MA stack (20<50<200)
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Peer Comparison
Specialty ChemicalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| PIDILITIND | Pidilite Industries Limited | ₹1,535.50 | +2.45% |
| SRF | SRF Limited | ₹2,743.00 | +3.18% |
| FLUOROCHEM | Gujarat Fluorochemicals Limited | ₹3,655.30 | -0.68% |
| NAVINFLUOR | Navin Fluorine International Limited | ₹7,303.00 | +2.04% |
| DEEPAKNTR | Deepak Nitrite Limited | ₹1,669.90 | +3.57% |
| ATUL | Atul Limited | ₹6,517.50 | +0.32% |
| AARTIIND | Aarti Industries Limited | ₹440.60 | +2.98% |
| AETHER | Aether Industries Limited | ₹1,142.90 | +1.25% |
| BASF | BASF India Limited | ₹3,356.50 | +3.21% |
| FINEORG | Fine Organic Industries Limited | ₹4,724.70 | +1.02% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 20 Sept 2024 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for PLATIND
View AllIndia raises price cap on cancer drugs to tackle shortage
India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused by a sharp rise in platinum costs. The National Pharmaceutical Pricing Authority (NPPA) approved the one-time hike in public interest after supply disruptions affected hospitals across the country.
Lenskart shares in focus as Goldman Sachs, Morgan Stanley, others purchase stake in Rs 1.960 crore block deal
Lenskart Solutions saw significant stake activity as marquee investors bought Rs 1,960 crore in a block deal, with Platinum Jasmine A 2018 Trust paring its holding. Despite recent exits, brokerages remain optimistic about Lenskart's long-term growth, citing its integrated model and international expansion.
Cancer drug prices raised 50% as NPPA acts on shortage concerns
India's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follows pleas from manufacturers citing soaring platinum costs. Anti-tetanus immunoglobulin drug prices also see an increase. The National Pharmaceutical Pricing Authority invoked special powers to ensure these life-saving medicines remain accessible to the public.